Mostrando entradas con la etiqueta bladder. Mostrar todas las entradas
Mostrando entradas con la etiqueta bladder. Mostrar todas las entradas

domingo, 18 de marzo de 2012

Run/walk against bladder cancer is Saturday in Oswego - Syracuse.com

Oswego, NY -- A run/walk to raise money to fight bladder cancer is being held at 10 a.m. Saturday in Oswego.

The "Run for Dennis" event honors Dennis Pacheco, of Oswego, who died of the disease March 17, 2011. A native of Rome, he was a long-time employee at the James FitzPatrick Nuclear Plant, coached soccer and baseball teams when his three children were young, was an avid motorcyclist and enjoyed motorsports, hunting, construction, woodworking and playing harmonica. He also liked all types of music, but especially enjoyed the blues and was known to do an impromptu Elvis impersonation on many occasions.

The race course is a 5K (3.1 miles) and begins at Gibby’s Irish Pub on Lake Street.

Go to this website link to register for the race. The cost now is $25 and $30 on Saturday morning.

Packet pickup is from 5 to 8 p.m. Friday at Gibby’s Irish Pub, 8 W. Second st., Oswego. Packet pickup also is available from 8 to 9:30 a.m. on race day.

Proceeds go to the Bladder Cancer Advocacy Network. Donations can be made to "Run For Dennis" and sent to Oswego County Federal Credit Union, P.O. Box 310, Oswego, 13126.


View the original article here

Summary of the 6th annual bladder cancer think tank: New directions in ... - UroToday

UroToday - Summary of the 6th annual bladder cancer think tank: New directions in urologic research - Abstract var base_url="http://www.urotoday.com/";
MARCH 17, 2012 Username

Password

Remember MeSubscribeForgot your password?Forgot your username? Quicklinks CAUTI ChallengeBladder Cancer Diagnosis & Monitoring CenterAdvanced Prostate Cancer Treatment Resource centerGU MalignanciesProstate CancerBladder CancerOveractive BladderFemale UrologyInfections advanced search HOMEConference CoverageEvent CalendarAdvanced SearchUroToday International Journal Browse CategoriesInvestigational UrologyProstate CancerRenal CancerBladder CancerEtiologyEpidemiologySymptoms & SignsDiagnosisPathologyNatural HistoryStagingBladder Cancer Diagnosis & Monitoring CenterCases, Prevalence, & MortalityGuidelines -Conference CoverageLinksTesticular CancerPenis & Urethra CancerBPH & Male LUTSErectile Dysfunction (ED)ProstatitisMale Infertility & ReproductionUrinary Incontinence (UI)Overactive BladderStress Urinary Incontinence (SUI)Female UrologyPeyronie's DiseaseIC/PBS/BPS/HBSStone DiseaseInfectionsUrologic Trauma and ReconstructionRenal Transplantation, Vascular DiseaseAdrenal and RetroperitoneumPediatric UrologyRelated TopicsGeriatric UrologyLaparoscopic & RoboticAndrogen DeficiencySexually Transmitted DiseaseDisease ResourcesFemale Sexual DysfunctionPelvic Floor RehabilitationCurrent Clinical Trials Home > Bladder Cancer #wrapper_photos,#mod_localnews_sports,#weather_photos{display:none;} Summary of the 6th annual bladder cancer think tank: New directions in urologic research - Abstract Thu, 15 March 2012 E-mail Print The 6th Annual Bladder Cancer Think Tank brought together a multidisciplinary group of clinicians, researchers, and representatives from the National Cancer Institute and Industry in an effort to advance bladder cancer research efforts.Username

Password

Remember MeSubscribeForgot your password?Forgot your username?
Your session will expire in 8 hours requiring you to log in each day to view content.
SUBMIT COMMENTS  * Please keep your comments relevant to the subject of the article
* The editors cannot answer queries or questions posted as comments
* Questions pertaining to specific health issues should be directed to a physician or medical professional

User Name: Your Title:Comment:

Verification: Type the characters you see in the picture below. Share| SubscribeNew User Create ProfileLogin & Subscribe NowSubscription InformationManage Your SubscriptionFAQsAbout UsEditors CornerBlogSlide LibraryPublication OpportunitiesUroToday ExclusivesBJU Int Mini ReviewsPublication LibraryGeneral FAQsBeyond the AbstractFeatured Conference

XXXIII Brazilian Congress of Urology

November 22 - 26, 2011
Santa Catarina, Brazil

Read More

4th World Congress on Controversies in Urology (CURy)

January 27 - 30, 2011

Paris, France

Read MoreUpcoming Conference

27th Annual European Association of Urology (EAU) Congress

February 24 - 28, 2012

Paris, France

Read More Home About Us About The Editors Sponsorship Opportunities Terms of Use Privacy Policy Services Report an Inaccuracy contact us Conference Highlights Events Resources Surgical Library Publication Library Slide Library Current Clinical Trials Links Case Studies Podcasts Centers of Excellence CAUTI Center Bladder Cancer Diagnosis & Monitoring Center GU Malignancies Center for Stones Disease Advanced Prostate Cancer Treatment Resource Center Careers + Training Educational Opportunities Sponsorship and Training Programs Position Offerings UroToday International Journal The Experts Digital Science Press Inc., 1741 Eighth Street, Berkeley, CA 94710 USA | fax: 510 540 0930  | E: info@urotoday.com | ISSN 1939-4810 | UroToday International Journal Correspondence

View the original article here

RhoGDI2 protein helps prevent bladder cancer metastasis to the lungs - News-Medical.net

The diagnosis of localized bladder cancer carries an 80 percent five-year survival rate, but once the cancer spreads, the survival rate at even three years is only 20 percent. A major study published today in the Journal of Clinical Investigation not only shows how bladder cancer metastasizes to the lungs but pinpoints a method for stopping this spread.

Specifically, the study shows that versican, a protein involved in cancer cell migration, is a driver of lung metastasis and that high levels of versican are associated with poor prognosis in bladder cancer patients. The study is the first to show how that when a cancer cell makes the protein RhoGDI2, it reduces the cell's production of versican, thus blocking the ability of the cancer cell to grow in the lungs.

"For a decade, we've known that the major challenge of treating bladder cancer is treating or preventing the metastatic form of the disease. This study represents an advance in the latter - by preventing the spread of bladder cancer to the lungs, we could improve patient survival," says Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center, the paper's senior author.

When a cancer metastasizes from its birth location to another, it's not necessarily that cells suddenly become mobile and thus able to float through the blood or lymph to new homes. In fact, these cancer cells may have been floating through a patient's blood for quite some time, and metastasis occurs only when one of these intrepid cells is finally able to grow in the place where it is attached, such as the lungs.

When the first cancer cells to attach to, say, the lung, they have a tough time - they become distressed. Cancer cells express this distress in the form of versican. And the more versican they express, the more help they get, which arrives in the form of macrophages, a part of the body's immune response that eat pathogens and other debris.

In most cases, the fact that macrophages benefit distressed cells is good, but in addition to helping healthy cells survive, these arriving macrophages also promote the growth of cancer cells that have landed in distant sites such as the lung, thus promoting metastasis of the disease.

More versican made by the cancer cells calls more macrophages, which aid cancer cells' survival and increase the likelihood that a cancer cell's toehold will develop into a clinically significant tumor in the lung.


View the original article here